• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DALANTERCEPT Drug Record

  • Summary
  • Interactions
  • Claims
  • DALANTERCEPT chembl:CHEMBL2109662 Antineoplastic

    Alternate Names:

    ACE-041
    DELANTERCEPT
    DALANTERCEPT

    Drug Info:

    FDA Approval not approved
    Drug Class fusion protein
    Drug Indications antineoplastic agent,antiangiogenic agent
    (3 More Sources)

    Publications:

    Hawinkels et al., 2016, Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors., Clin. Cancer Res.
    Makker et al., 2015, Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N., Gynecol. Oncol.
  • DALANTERCEPT   GDF2

    Interaction Score: 46.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Growth/differentiation factor 2 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial ChemblInteractions TTD

  • DALANTERCEPT   BMP10

    Interaction Score: 30.91

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Bone morphogenetic protein 10 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial ChemblInteractions

  • DALANTERCEPT   ACVRL1

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name ACE-041
    Novel drug target Novel Target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ClearityFoundationClinicalTrial

  • DALANTERCEPT   ALK

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Dalantercept + Cisplatin
    Indication/Tumor Type breast cancer
    Response Type predicted – sensitive

    PMIDs:
    26373572 25888978


    Sources:
    JAX-CKB

  • TdgClinicalTrial: DALANTERCEPT

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent,antiangiogenic agent
    Drug Class fusion protein
    FDA Approval not approved

    Publications:

  • JAX-CKB: Dalantercept

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Hawinkels et al., 2016, Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors., Clin. Cancer Res.

  • JAX-CKB: dalantercept

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Makker et al., 2015, Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N., Gynecol. Oncol.

  • TTD: ACE-041

    • Version: 2020.06.01

    Alternate Names:
    D0N9PL TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL2109662

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL2109662

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: DALANTERCEPT

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21